Retrospective Analysis of Mycophenolate Mofetil in Generalized Myasthenia Gravis

2021 ◽  
Vol 23 (2) ◽  
pp. 112-113
Author(s):  
Shaweta Khosa ◽  
Shri K. Mishra ◽  
Ariel Jablonow ◽  
Robert Freundlich
Keyword(s):  
Mycophenolate Mofetil ◽  
Myasthenia Gravis ◽  
Retrospective Analysis

Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients

2010 ◽  
Vol 41 (5) ◽  
pp. 593-598 ◽  
Author(s):  
Michael K. Hehir ◽  
Ted M. Burns ◽  
Joshua Alpers ◽  
Mark R. Conaway ◽  
Michael Sawa ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Myasthenia Gravis ◽  
Achr Antibody

scholarly journals Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database

2015 ◽  
Vol 49 (5) ◽  
pp. 1510-1515 ◽  
Author(s):  
Jun Nakajima ◽  
Meinoshin Okumura ◽  
Motoki Yano ◽  
Hiroshi Date ◽  
Takuya Onuki ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Epithelial Tumour

scholarly journals Methotrexate Use in Generalized Autoimmune Myasthenia Gravis: A Case series

2021 ◽  
Vol 2 (5) ◽  
Author(s):  
Preston Eibling ◽  
Yuebing Li ◽  
Robert Marquardt
Keyword(s):  
Side Effects ◽  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Acetylcholine Receptor ◽  
Average Duration ◽  
Case Series ◽  
Immunosuppressive Medication ◽  
Autoimmune Myasthenia ◽  
Sparing Effect ◽  
Steroid Sparing

Methotrexate (MTX) is an inexpensive and well-tolerated immunosuppressive medication that is used anecdotally in autoimmune myasthenia gravis (MG). However, the efficacy in MG is unclear at this time. This retrospective analysis describes six patients with acetylcholine receptor antibody positive MG who were treated with MTX and corticosteroids. The efficacy of MTX was measured by steroid-sparing effect and the Myasthenia Gravis Foundation of America (MGFA) classification. MTX initiation was associated with a reduction in prednisone dosage in all patients. Minimal manifestation status was reached at an average duration of 10 months in 5 patients.  No patients were hospitalized for myasthenia gravis exacerbations. There were no major side effects experienced with MTX use.  This retrospective analysis suggests that MTX is safe and probably efficacious as a corticosteroid-sparing agent in the management of MG.

Retrospective Analysis of Safety and Outcomes of Rituximab for Myasthenia Gravis in Patients ≥ 65 Years Old

2021 ◽  
Author(s):  
Christopher T. Doughty ◽  
Joome Suh ◽  
William S. David ◽  
Anthony A. Amato ◽  
Amanda C. Guidon
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis
Sign in / Sign up

Export Citation Format

Share Document